The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / California Insurance Commissioner Urges U.S. to Block Anthem-Cigna Deal

California Insurance Commissioner Urges U.S. to Block Anthem-Cigna Deal

June 19, 2016 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—California’s insurance commissioner on Thursday urged the U.S. Department of Justice (DOJ) to block health insurer Anthem Inc.’s acquisition of Cigna Corp., saying he is concerned it will raise premiums in the state.

You Might Also Like
  • U.S. Regulators Sue to Block Anthem-Cigna & Aetna-Humana Mergers
  • U.S. Court Blocks Anthem-Cigna Deal
  • U.S. Hospitals Urge DOJ Antitrust Probe of Anthem-Cigna Deal

Dave Jones, who as insurance commissioner in California does not have authority to approve the deal, says he believes his recommendation will hold weight with U.S. antitrust regulators examining the acquisition.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Anthem announced plans to buy Cigna last summer. Recently, Anthem said it believed the Justice Department was examining the employer-based health insurance market in which the insurer acts as the health plan administrator.

In California, Anthem and Cigna would control 61% of the administrative services market alone, Jones said during a call with reporters.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“California has a highly consolidated insurance market today. This merger with Anthem and Cigna will only make that situation worse,” Jones said. He said there were no divestitures that could improve the situation.

In a letter to the Justice Department, Jones described California’s $122.9 billion health insurance market as “highly concentrated,” and accused Anthem of “a history of implementing substantial and unreasonable premium increases in California.”

Anthem disagreed with Jones.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“We do not believe that the California Department of Insurance‘s opinion is based on the true merits of this transaction,” the company said in a statement. “We are confident that the highly complementary nature and limited overlap of our organizations that will benefit the complex and competitive health insurance markets will be reviewed on the facts by the DOJ and appropriate state authorities.”

The deal is one of two major mergers being contemplated in the health insurance market. The other is Aetna’s planned $33 billion tie-up with Humana.

Filed Under: Legal, Professional Topics Tagged With: Anthem Inc., California, Cigna Corp., Health Insurance, insurer, merger

You Might Also Like:
  • U.S. Regulators Sue to Block Anthem-Cigna & Aetna-Humana Mergers
  • U.S. Court Blocks Anthem-Cigna Deal
  • U.S. Hospitals Urge DOJ Antitrust Probe of Anthem-Cigna Deal
  • U.S. Hospital Group Warns of Blue Cross Dominance if Anthem Buys Cigna

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)